Agenus Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGEN research report →
About the company
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
- CEO
- Garo H. Armen
- IPO
- 2000
- Employees
- 316
- HQ
- Lexington, MA, US
Price Chart
- Market Cap
- $145.33M
- P/E
- 2.05
- P/S
- 1.17
- P/B
- -0.60
- EV/EBITDA
- 3.27
- Div Yield
- 0.00%
- Gross Margin
- 52.14%
- Op Margin
- 6.62%
- Net Margin
- 52.16%
- ROE
- -23.05%
- ROIC
- 10.53%
- Revenue
- $114.20M · 10.37%
- Net Income
- $115.00K · 100.05%
- EPS
- $-0.00 · 99.97%
- Op Income
- $-20,556,000
- FCF YoY
- 0.00%
- 52W High
- $7.34
- 52W Low
- $2.71
- 50D MA
- $3.41
- 200D MA
- $3.67
- Beta
- 1.54
- Avg Volume
- 945.90K
Get TickerSpark's AI analysis on AGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | ARMEN GARO H | other | 5,364 |
| Jun 12, 26 | ARMEN GARO H | other | 4,925 |
| May 29, 26 | ARMEN GARO H | other | 4,644 |
| May 15, 26 | ARMEN GARO H | other | 4,540 |
| May 1, 26 | ARMEN GARO H | other | 4,233 |
| Apr 24, 26 | Hirsch Susan B | other | 105,000 |
| Apr 24, 26 | Buell Jennifer | other | 300,000 |
| Apr 24, 26 | Buell Jennifer | other | 5,000 |
| Apr 24, 26 | O'Day Steven J | other | 95,333 |
| Apr 24, 26 | O'Day Steven J | other | 70,000 |
Our AGEN coverage
Recent articles, reports, and earnings notes.
No research on AGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGEN report →Similar companies
Peers in the same neighborhood.